Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.65M
Average 0.39M
Returns on capital
Sionna Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-24.5%
avg 28.0%
ROIC
-28.2%
avg -58.3%
ROA
-23.1%
avg -48.3%
Analysis
ROA is currently the strongest return metric at -23.1% versus its period average of -48.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Michael Cloonan | President, Chief Executive Officer & Director | USD 1.03M | 55 | 0 | <0.01% |
Elena H. Ridloff | CFO & Chief Business Officer | USD 771.6K | 46 | — | — |
Charlotte McKee | Chief Medical Officer & Head of Research and Development | USD 647.92K | 61 | 0 | <0.01% |
Caroline Stark Beer | Chief Business Officer | USD 268.11K | 47 | 139.34K | 0.31% |
Mark Munson | Co-founder | — | — | — | — |
Roxanne McGrath | Vice President of Head of Human Resources | — | — | — | — |
Juliet Labadorf | Senior Director of Investor Relations & Corporate Development | — | — | — | — |
Kenneth A. Lock | Chief Commercial Officer | — | 52 | — | — |
Mark Trone | Senior VP & Head of CMC | — | — | — | — |
Cecile Le Camus | VP & Head of Medical Affairs | — | — | — | — |
Erica Iorio | VP of Finance & Controller | — | — | — | — |
Jennifer Fitzpatrick | Chief Legal Officer & Head of Program Management | — | 49 | 0 | <0.01% |
Mara Furlow | Senior Vice President of Global Regulatory Affairs & Quality | — | — | — | — |
Meghan Bagshaw | Vice President & Chief of Staff to CMO | — | — | — | — |
Greg Hurlbut | Co-Founder & Senior Vice President of Discovery Research | — | — | — | — |
Andy Chu | Vice President of Information & Technology | — | — | — | — |
Sarah J. Spencer | Vice President of Corporate Communications | — | — | — | — |
Vanya Sagar | Chief People Officer | — | 50 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
58
$145.59M
Net Transaction Value
−$145.59M
Net selling
Most Active
Thompson Peter A.
20 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 17, 26Sep 17, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $252.1K$252,148.00 |
| Sep 17, 26Sep 17, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $21.6M$21,582,869.52 |
| Jul 7, 26Jul 7, 2026 | Thompson Peter A. Indirect | Sell | $3.9M$3,854,281.48 |
| Jul 7, 26Jul 7, 2026 | ORBIMED ADVISORS LLC Indirect | Sell | $3.9M$3,854,281.48 |
| Jul 6, 26Jul 6, 2026 | Fitzpatrick Jennifer Direct | Sell | $446.9K$446,862.08 |
| Jun 30, 26Jun 30, 2026 | ORBIMED ADVISORS LLC Indirect | Sell | $5.3M$5,270,902.00 |
| Jun 30, 26Jun 30, 2026 | Thompson Peter A. Indirect | Sell | $5.3M$5,270,902.00 |
| May 27, 26May 27, 2026 | Thompson Peter A. Indirect | Sell | $4.5K$4,493.49 |
| May 27, 26May 27, 2026 | ORBIMED ADVISORS LLC Indirect | Sell | $4.5K$4,493.49 |
| May 11, 26May 11, 2026 | ORBIMED ADVISORS LLC Indirect | Sell | $8.5M$8,534,014.58 |
1–10 of 58
Summary
Insiders reported 0 buys worth $0.00 and 58 sells worth $145.59M over the last 12 months. That adds up to net selling of $145.59M. Thompson Peter A. was the most active insider with 20 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Sionna Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about SION's management, answered from reported figures.
Who manages SION?
Sionna Therapeutics, Inc. (SION) lists 18 active executives. The top listed executive is Mark Munson, Co-founder.
Are SION insiders buying or selling?
Recent insider activity shows net selling of $167.67M.
Continue the stock analysis
Jump to another research area for this company.